F3 Platform Biologics, Inc. (JDRR)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	n/a
Revenue (ttm)	n/a
Net Income (ttm)	-1.09M
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About JDRR

F3 Platform Biologics is a late-stage biopharmaceutical company committed to the development and commercialization of novel, practical biotechnology for human use. We are focused on the research, clinical development, and ultimate commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. Amifostine has been shown to repair and protect against human cell mutation and dest...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 3
• Stock Exchange: NASDAQ
• Ticker Symbol: JDRR
• Website: https://www.f3pb.com/